Success Story | Kantify Selected For Horizon Europe Funding

95% of rare diseases still do not have therapy, but artificial intelligence is now able to change the situation. Kantify, a pioneering startup in artificial intelligence, in collaboration with I-Stem, one of the European leaders in stem cell research, has the ambition to accelerate rare disease drug discovery through the newly launched and symbolically named “DREAMS” project funded by the European Commission through a highly competitive call for proposals under Horizon Europe Cluster Health. The partners have the ambition to revolutionize the field by combining Kantify’s novel AI technology with induced pluripotent stem cells.

Therefore, the consortium aims to discover 5 drugs for 5 rare neuromuscular diseases (and perhaps even more) in less than 5 years. An ambitious objective made possible thanks to Artificial Intelligence.

NCP Brussels support

Several NCP Brussels advisors supported Kantify in the highly competitive application process. This individualised support mainly consisted of several proofreading sessions over the different application rounds and guidance on administrative, legal and financial questions.

Are you Brussels-based and do you also want to use our free of charge services to help you benefit from EU funding by setting-up, executing and exploiting successful R&I projects? Do not hesitate to contact us.

BACKGROUND

About Kantify

Kantify is a Belgian artificial intelligence “TechBio” company with the mission to improve human health with Artificial Intelligence. Founded by Segolene Martin and Nik Subramanian, Kantify specializes in AI-powered drug discovery to accelerate the development of new drugs.

About The Dreams Consortium

The DREAMS (Drug REpurposing and Artificial intelligence for Muscular disorders), consortium, funded by the European Commission through Horizon Europe, brings together leading experts and organizations to pioneer a novel approach to rare disease drug discovery. The project is coordinated by I-Stem, the French stem cell research center, and Kantify, the Belgian pioneering ‘TechBio’ specialised in AI powered drug discovery.

The DREAMS consortium unites a highly skilled and complementary consortium of nine European partners, encompassing clinicians, patients, academic researchers, and private stakeholders.

These organizations include:

1. I-Stem (France) – Coordinator
2. Kantify (Belgium) – Co-coordinator
3. The Institute of Myology (France)
4. Center for Neuroscience and Cell Biology – University of Coimbra (Portugal).
5. The Technion – Israel Institute of Technology (Israel).
6. Samsara Therapeutics (UK)
7. Assistance Publique – Hôpitaux de Paris (France).
8. AFM-Telethon (France).
9. Zabala Innovation (Spain)